CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
25.7%
16M of 63M shares
Institutional holders
51
8 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
10 buys · 0 sales
Net bought $269.33K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Avenir Corp | 5,230,099 | 8.30% | 13G (passive) amendment | Dec 31, 2025 |
| Thomas A. Satterfield, Jr. | 3,998,867 | 6.56% | 13G (passive) | Jan 13, 2025 |
| Avenue Capital Management II, L.P. | 3,755,273 | 5.70% | 13G (passive) | Jun 26, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTSO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Avenir Corp | 5,189,218 | 8.26% | $1.94M | −26,558 | 0.24% |
| Neuberger Berman Group LLC | 1,968,691 | 3.13% | $740.52K | +285,684 | 0.00% |
| Vanguard Capital Management LLC | 1,914,063 | 3.05% | $715.86K | +34,074 | 0.00% |
| CM Management, LLC | 1,476,500 | 2.35% | $552.21K | – | 0.37% |
| Skylands Capital, LLC | 1,211,400 | 1.93% | $453.06K | −496,098 | 0.06% |
| BlackRock, Inc. | 627,211 | 1.00% | $234.58K | −155,781 | 0.00% |
| Geode Capital Management, LLC | 602,059 | 0.96% | $225.24K | −105,203 | 0.00% |
| Sargent Investment Group, LLC | 555,757 | 0.88% | $207.85K | +5,857 | 0.02% |
| Pathstone Holdings, LLC | 499,910 | 0.80% | $186.97K | −45 | 0.00% |
| Vanguard Fiduciary Trust Co | 316,167 | 0.50% | $118.25K | +2,311 | 0.00% |
| CIBC Bancorp USA Inc. | 172,649 | 0.27% | $64.57K | – | 0.00% |
| State Street Corp | 159,293 | 0.25% | $59.58K | – | 0.00% |
| Osaic Holdings, Inc. | 134,839 | 0.21% | $49.99K | +4,420 | 0.00% |
| UBS Group AG | 131,019 | 0.21% | $49.00K | +15,819 | 0.00% |
| Northern Trust Corp | 111,660 | 0.18% | $41.76K | +19,120 | 0.00% |
| Raymond James Financial Inc | 107,611 | 0.17% | $40.25K | −140 | 0.00% |
| NWF Advisory Services Inc. | 104,139 | 0.17% | $38.95K | – | 0.00% |
| Renaissance Technologies LLC | 100,020 | 0.16% | $37.41K | −700 | 0.00% |
| Morgan Stanley | 91,338 | 0.15% | $34.16K | −8,831 | 0.00% |
| Key Client Fiduciary Advisors, LLC | 78,457 | 0.12% | $29.34K | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 51 | 16M | 25.7% | 8 / 11 | 13 / 7 | 1M | 1M |
| Q1 2026 | 50 | 16M | 26.2% | 10 / 9 | 12 / 7 | 3M | 1M |
| Q4 2025 | 51 | 17M | 26.8% | 9 / 14 | 11 / 6 | 1M | 1M |
| Q3 2025 | 49 | 16M | 26.0% | 8 / 13 | 11 / 3 | 0M | 1M |
| Q2 2025 | 45 | 16M | 26.2% | 3 / 8 | 18 / 7 | 1M | 1M |
| Q1 2025 | 49 | 17M | 27.0% | 7 / 18 | 9 / 9 | 3M | 1M |
| Q4 2024 | 51 | 15M | 24.4% | 12 / 13 | 11 / 12 | 1M | 2M |
| Q3 2024 | 53 | 16M | 26.2% | 9 / 9 | 13 / 5 | 1M | 1M |
| Q2 2024 | 50 | 17M | 26.5% | 3 / 8 | 18 / 3 | 0M | 1M |
| Q1 2024 | 50 | 18M | 28.4% | 2 / 15 | 15 / 6 | 1M | 1M |
| Q4 2023 | 54 | 18M | 28.9% | 8 / 16 | 14 / 6 | 4M | 0M |
| Q3 2023 | 53 | 15M | 24.2% | 7 / 12 | 16 / 11 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CTSO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,274,363 | 2.03% | $476.61K | 0.00% | Jun 30, 2026 |
| Neuberger Intrinsic Value Fund | 646,511 | 1.03% | $317.37K | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 574,463 | 0.91% | $214.85K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 380,268 | 0.61% | $186.67K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 94,319 | 0.15% | $46.30K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 78,580 | 0.13% | $38.57K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 35,641 | 0.06% | $13.33K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 32,102 | 0.05% | $15.76K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 29,596 | 0.05% | $11.07K | 0.00% | Jun 30, 2026 |
| Morgan Stanley Pathway Small-Mid Cap Equity ETF | 21,766 | 0.03% | $10.68K | 0.00% | May 31, 2026 |
| Column Small Cap Select Fund | 6,741 | 0.01% | $3.31K | 0.00% | May 31, 2026 |
| Column Small Cap Fund | 2,079 | 0.00% | $1.02K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Phillip P. Chan | Chief Executive Officer, Director | 100,996 | 0.16% | Sep 16, 2026 |
| Vincent Capponi | President and COO | 40,114 | 0.06% | Sep 16, 2026 |
| Peter J. Mariani | Chief Financial Officer | 638,113 | 1.02% | Jun 16, 2026 |
| Efthymios Deliargyris | Chief Medical Officer | 473,025 | 0.75% | Aug 8, 2025 |
| Alan D. Sobel | Director | 11,787 | 0.02% | Sep 16, 2026 |
| Jiny Kim | Director | 77,819 | 0.12% | Aug 8, 2025 |
| Edward Raymond Jones | Director | 88,834 | 0.14% | Aug 8, 2025 |
| Michael G. Bator | Director | 151,273 | 0.24% | Aug 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alan D. Sobel Director | Sep 15, 2026 | Buy | +500 | $6.05 | $3.03K | 9,787 |
| Alan D. Sobel Director | Sep 15, 2026 | Buy | +1,900 | $6.12 | $11.63K | 9,287 |
| Alan D. Sobel Director | Sep 15, 2026 | Buy | +100 | $6.01 | $601 | 9,887 |
| Phillip P. Chan Chief Executive Officer, Director | Sep 15, 2026 | Buy | +3,774 | $6.00 | $22.64K | 100,996 |
| Vincent Capponi President and COO | Sep 14, 2026 | Buy | +1,800 | $6.07 | $10.93K | 40,114 |
| Vincent Capponi President and COO | Sep 14, 2026 | Buy | +273 | $5.90 | $1.61K | 40,387 |
| Phillip P. Chan Chief Executive Officer, Director | Sep 4, 2026 | Buy | +200,000 | $0.35 | $70.00K | 1,944,432 |
| Peter J. Mariani Chief Financial Officer | Jun 15, 2026 | Buy | +100,000 | $0.44 | $44.00K | 638,113 |
| Phillip P. Chan Chief Executive Officer, Director | Jun 15, 2026 | Buy | +10,333 | $0.43 | $4.44K | 1,744,432 |
| Phillip P. Chan Chief Executive Officer, Director | Jun 12, 2026 | Buy | +251,136 | $0.40 | $100.45K | 1,734,099 |
| Phillip P. Chan Chief Executive Officer, Director | Nov 18, 2025 | Award | +100,000 | $0.64 | $64.00K | 1,482,963 |
| Peter J. Mariani Chief Financial Officer | Aug 8, 2025 | Award | +71,500 | – | – | 538,113 |
| Vincent Capponi President and COO | Aug 8, 2025 | Award | +89,100 | – | – | 766,268 |
| Phillip P. Chan Chief Executive Officer, Director | Aug 8, 2025 | Award | +105,600 | – | – | 1,382,963 |
| Efthymios Deliargyris Chief Medical Officer | Aug 8, 2025 | Award | +70,000 | – | – | 473,025 |
| Michael G. Bator Director | Feb 24, 2025 | Exercise | +10,000 | $1.13 | $11.30K | 151,273 |
| Alan D. Sobel Director | Feb 24, 2025 | Exercise | +21,950 | $1.13 | $24.80K | 145,757 |
| Phillip P. Chan Chief Executive Officer, Director | Feb 24, 2025 | Exercise | +34,168 | $1.13 | $38.61K | 1,277,363 |
| Vincent Capponi President and COO | Feb 24, 2025 | Exercise | +12,000 | $1.13 | $13.56K | 677,168 |
| Peter J. Mariani Chief Financial Officer | Feb 24, 2025 | Exercise | +32,625 | $1.13 | $36.87K | 466,613 |
| Michael G. Bator Director | Jan 17, 2025 | Option exercise | +15,879 | $1.00 | $15.88K | 141,273 |
| Vincent Capponi President and COO | Jan 17, 2025 | Option exercise | +31,760 | $1.00 | $31.76K | 665,168 |
| Alan D. Sobel Director | Jan 17, 2025 | Option exercise | +21,950 | $1.00 | $21.95K | 123,807 |
| Peter J. Mariani Chief Financial Officer | Jan 17, 2025 | Option exercise | +32,625 | $1.00 | $32.63K | 433,988 |
| Efthymios Deliargyris Chief Medical Officer | Jan 17, 2025 | Option exercise | +16,233 | $1.00 | $16.23K | 403,025 |
| Phillip P. Chan Chief Executive Officer, Director | Jan 17, 2025 | Option exercise | +90,832 | $1.00 | $90.83K | 1,243,195 |
| Peter J. Mariani Chief Financial Officer | Dec 13, 2024 | Buy | +20,000 | $0.96 | $19.20K | 401,363 |
| Peter J. Mariani Chief Financial Officer | Dec 12, 2024 | Buy | +20,000 | $0.89 | $17.80K | 381,363 |
| Peter J. Mariani Chief Financial Officer | Dec 11, 2024 | Buy | +11,363 | $0.89 | $10.11K | 361,363 |
| Peter J. Mariani Chief Financial Officer | Aug 14, 2024 | Award | +110,000 | – | – | 110,000 |
| Peter J. Mariani Chief Financial Officer | Aug 14, 2024 | Award | +65,000 | – | – | 175,000 |
| Peter J. Mariani Chief Financial Officer | Aug 14, 2024 | Award | +175,000 | – | – | 350,000 |
| Vincent Capponi President and COO | Apr 2, 2024 | Award | +81,000 | – | – | 665,134 |
| Efthymios Deliargyris Chief Medical Officer | Apr 2, 2024 | Award | +61,000 | – | – | 409,433 |
| Phillip P. Chan Chief Executive Officer, Director | Apr 2, 2024 | Award | +96,000 | – | – | 1,164,704 |
| Kathleen P. Bloch Chief Financial Officer | Apr 2, 2024 | Award | +65,000 | – | – | 532,941 |
| Vincent Capponi President & COO | Dec 13, 2023 | Buy | +18,797 | $1.33 | $25.00K | 584,134 |
| Kathleen P. Bloch Chief Financial Officer | Dec 13, 2023 | Buy | +37,594 | $1.33 | $50.00K | 467,941 |
| Edward Raymond Jones Director | Dec 13, 2023 | Buy | +7,519 | $1.33 | $10.00K | 88,834 |
| Jiny Kim Director | Dec 13, 2023 | Buy | +7,519 | $1.33 | $10.00K | 77,819 |
| Michael G. Bator Director | Dec 13, 2023 | Buy | +37,594 | $1.33 | $50.00K | 125,394 |
| Phillip P. Chan Chief Executive Officer, Director | Dec 13, 2023 | Buy | +75,188 | $1.33 | $100.00K | 1,068,704 |
| Efthymios Deliargyris Chief Medical Officer | Dec 13, 2023 | Buy | +22,557 | $1.33 | $30.00K | 348,433 |
| Alan D. Sobel Director | Dec 13, 2023 | Buy | +22,557 | $1.33 | $30.00K | 101,857 |
| Kathleen P. Bloch Chief Financial Officer | Sep 18, 2023 | Award | +45,000 | – | – | 442,347 |
| Michael G. Bator Director | Aug 7, 2023 | Buy | +1,000 | $3.20 | $3.20K | 86,800 |
| Michael G. Bator Director | Aug 7, 2023 | Buy | +1,000 | $3.15 | $3.15K | 87,800 |
| Michael G. Bator Director | Aug 4, 2023 | Buy | +1,000 | $3.23 | $3.23K | 85,800 |
| Phillip P. Chan Chief Executive Officer, Director | Jul 7, 2023 | Award | +87,000 | – | – | 1,006,548 |
| Efthymios Deliargyris Chief Medical Officer | Jul 7, 2023 | Award | +55,000 | – | – | 331,648 |
| Vincent Capponi President & COO | Jul 7, 2023 | Award | +73,000 | – | – | 576,153 |
| Kathleen P. Bloch Interim CFO | May 25, 2023 | Buy | +1,100 | $2.85 | $3.14K | 47,000 |
| Kathleen P. Bloch Interim CFO | May 25, 2023 | Buy | +1,100 | $2.84 | $3.12K | 45,900 |
| Kathleen P. Bloch Interim CFO | May 25, 2023 | Buy | +1,100 | $2.85 | $3.14K | 44,800 |
| Kathleen P. Bloch Interim CFO | May 10, 2023 | Buy | +2,000 | $3.13 | $6.26K | 40,700 |
| Kathleen P. Bloch Interim CFO | May 10, 2023 | Buy | +3,000 | $3.17 | $9.51K | 43,700 |
| Kathleen P. Bloch Interim CFO | May 10, 2023 | Buy | +5,000 | $3.06 | $15.30K | 38,700 |
| Vincent Capponi See Remarks | Apr 4, 2023 | Option exercise | +10,000 | $2.88 | $28.80K | 511,989 |
| Phillip P. Chan Chief Executive Officer | Apr 3, 2023 | Option exercise | +30,500 | $2.88 | $87.84K | 927,779 |
| Alan D. Sobel Director | Feb 27, 2023 | Gift | +2,000 | – | – | 81,300 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter J. Mariani Officer | Aug 19, 2025 | 10,548 | $11.45K | Aug 19, 2025 | Restricted Stock Vesting |